Company profile for Pharosgen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pharosgen is a cancer-focused biotech company currently conducting a Phase 1 clinical trial for PGP 2113 (MPD-1) in patients with advanced solid tumors harboring KRAS mutations and PTEN loss. The company is developing two novel therapies: a biomarker-driven Peptide-Drug Conjugate (PDC) and an Antibody-Drug Conjugate (ADC). Collaborating with top institutions like Seoul National University, Ulsan National University, and KIST, ...
Pharosgen is a cancer-focused biotech company currently conducting a Phase 1 clinical trial for PGP 2113 (MPD-1) in patients with advanced solid tumors harboring KRAS mutations and PTEN loss. The company is developing two novel therapies: a biomarker-driven Peptide-Drug Conjugate (PDC) and an Antibody-Drug Conjugate (ADC). Collaborating with top institutions like Seoul National University, Ulsan National University, and KIST, Pharosgen leverages cutting-edge technology to pioneer innovative cancer treatments that aim to impact patients globally

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
404, 2nd Building, 387, Wiryesunhwan-ro, Songpa-gu, Seoul
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty